Gossamer Bio FY2024 EPS Estimate Increased by HC Wainwright

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities researchers at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Gossamer Bio in a research report issued on Monday, November 11th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($0.18) for the year, up from their prior forecast of ($0.21). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Gossamer Bio’s Q4 2024 earnings at ($0.08) EPS, Q2 2025 earnings at ($0.16) EPS, Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.52) EPS, FY2026 earnings at ($0.18) EPS, FY2027 earnings at ($0.01) EPS and FY2028 earnings at $0.28 EPS.

Separately, Wedbush reissued an “outperform” rating and issued a $4.00 price target on shares of Gossamer Bio in a report on Tuesday, August 13th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Trading Down 3.8 %

Shares of Gossamer Bio stock opened at $0.82 on Wednesday. The business has a 50 day moving average price of $0.94 and a 200 day moving average price of $0.86. The company has a market capitalization of $184.81 million, a P/E ratio of -2.55 and a beta of 1.96. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. Gossamer Bio has a 1 year low of $0.50 and a 1 year high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.04. The business had revenue of $9.48 million for the quarter, compared to analyst estimates of $4.52 million.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in GOSS. The Manufacturers Life Insurance Company increased its stake in Gossamer Bio by 24.2% in the third quarter. The Manufacturers Life Insurance Company now owns 385,133 shares of the company’s stock valued at $380,000 after purchasing an additional 74,920 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Gossamer Bio during the 3rd quarter valued at about $67,000. US Bancorp DE acquired a new position in shares of Gossamer Bio during the 3rd quarter valued at about $39,000. Sequoia Financial Advisors LLC lifted its holdings in shares of Gossamer Bio by 26.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock worth $117,000 after acquiring an additional 25,000 shares during the period. Finally, Algert Global LLC acquired a new stake in shares of Gossamer Bio in the second quarter worth approximately $75,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.